GLP-1 generations: one receptor, two, three - and the amylin alternative

TL;DR

• Each generation added a receptor - semaglutide one, tirzepatide two, retatrutide three; cagrilintide takes the amylin route instead.
• Only semaglutide and tirzepatide are approved and prescribable - retatrutide and CagriSema are not.
• Semaglutide holds the only proven mortality benefit - SELECT, over 17,000 adults: 20% fewer major cardiovascular events, 19% fewer deaths from any cause.
• Tirzepatide is the most effective approved option - about 21% in SURMOUNT-1, and 94% less progression to type 2 diabetes in prediabetes follow-up.
• Retatrutide reported the largest figures - 28.3% at 80 weeks in TRIUMPH-1 - but is unapproved everywhere and cannot legally be compounded.
• The page's only true head-to-head went to tirzepatide - REDEFINE-4: CagriSema 23.0% versus 25.5% at 84 weeks, missing non-inferiority.

Educational content, not medical advice. No doses or protocols appear. Approval status is stated as of August 2026 and is changing quickly. Two of the four compounds here are investigational and not available by prescription.

Updated September 2026: corrects the REDEFINE 4 figures to 23.0% vs 25.5% at 84 weeks, bringing this page into line with the canonical figures carried on the CagriSema and cagrilintide pages, and states the missed endpoint as the primary endpoint of non-inferiority on weight loss against Zepbound (tirzepatide) at its highest approved dose. Adds lastupdated and last_reviewed, which this file previously lacked._

---

The story of this drug class is unusually clean: each generation added a receptor, and each addition produced more weight loss. Semaglutide activates one hormone pathway. Tirzepatide activates two. Retatrutide activates three. Cagrilintide takes a different route entirely - a separate satiety hormone, designed to be paired with a GLP-1 rather than replace it.

That pattern is the single most useful thing to understand, because it explains both why the newer compounds work better and why "just wait for the next one" is a worse plan than it sounds.

Completing the 2026 picture: TRIUMPH-3 (obesity with established cardiovascular disease) reported about 22.6%, and TRIUMPH-1's extension reported roughly 30.3% at 104 weeks at the highest dose studied - the largest figure reported in the programme.

The comparison at a glance

Numbers come from different trials in different populations and are not head-to-head comparisons - with one important exception noted below.

Generation one: semaglutide

Semaglutide mimics GLP-1, a hormone the gut releases after eating: it slows gastric emptying, increases satiety and improves insulin secretion. Approved for type 2 diabetes in 2017 (Ozempic) and for chronic weight management in 2021 (Wegovy), it produced roughly 15% mean weight loss in the STEP programme.

But the trial that matters most isn't a weight-loss trial. SELECT enrolled over 17,000 adults with established cardiovascular disease and overweight or obesity and asked whether semaglutide reduced heart attacks, strokes and cardiovascular death. It did - a 20% relative reduction in major adverse cardiovascular events and a 19% reduction in death from any cause. That's why the FDA expanded the label in 2024 to include cardiovascular risk reduction.

This is the point most comparison articles miss: semaglutide is not simply the weakest option on the list. It is the only one on this page with a proven mortality benefit. Newer compounds produce more weight loss; none of them has yet shown they help you live longer. (Full guide.)

Generation two: tirzepatide

Tirzepatide adds a second pathway - GIP, another gut hormone involved in insulin secretion and fat metabolism - alongside GLP-1 (see the tirzepatide compound reference). Approved as Mounjaro for type 2 diabetes (2022) and Zepbound for weight management (2023), it is currently the most effective FDA-approved weight-loss medication available.

In SURMOUNT-1, participants without diabetes lost a mean of around 21% of body weight at the highest dose over 72 weeks, versus roughly 3% on placebo. In extended follow-up among participants with prediabetes, it reduced progression to type 2 diabetes by 94% relative to placebo - an enormous effect that gets far less attention than the weight numbers.

The dual-receptor mechanism is why tirzepatide consistently outperforms single-receptor GLP-1s head-to-head - and it is also why its effects turn up in so many tissues at once, which is the subject of what tirzepatide is actually doing organ by organ. (Full guide · vs retatrutide.)

Generation three: retatrutide (investigational)

Retatrutide adds a third receptor: glucagon, alongside GLP-1 and GIP. The mechanistic logic is genuinely different rather than just "more of the same" - GLP-1 and GIP activation reduce caloric intake through appetite centres, while glucagon receptor activation independently increases resting energy expenditure and fat oxidation. Combining reduced intake with increased expenditure is why the numbers outpace GLP-1-alone drugs.

The phase 2 trial (New England Journal of Medicine, 2023) showed 24.2% mean weight loss at 48 weeks. Phase 3 has now read out, and the results are the largest recorded for a single obesity medication:

• TRIUMPH-1 - 2,339 adults without diabetes: 28.3% mean weight loss at 80 weeks (reported May 2026)
• TRIUMPH-4 - adults with obesity and knee osteoarthritis: 28.7% at 68 weeks, with meaningful improvement in pain scores
• TRIUMPH-2 and -3 - approximately 20.8% and 22.6%
• TRANSCEND-T2D-1 - in type 2 diabetes: 16.8% weight loss and up to a 2.0-point HbA1c reduction at 40 weeks
• A sleep apnoea substudy reported a 60.6% reduction in AHI from a severe baseline

The honest framing. Retatrutide is not approved - not by the FDA, not by the EMA, not anywhere. Lilly is expected to file in early 2027, which puts realistic availability in 2028. The FDA has stated it is not a component of any approved drug and cannot legally be compounded. Tolerability also scales with efficacy: discontinuation due to side effects ran around 11% at the highest dose versus about 5% on placebo.

Anything sold as "retatrutide" today is outside the regulated supply chain, with no guarantee of identity, purity or sterility. That is a materially different proposition from a prescribed, approved medicine. (Full guide · the evidence.)

A note on naming: you'll see retatrutide marketed as "GLP-3." That isn't a real drug class - there is no third GLP hormone. It's a coinage that obscures which compound you're actually being sold. Treat it as a marketing signal, not a scientific one.

The alternative route: cagrilintide and CagriSema

Cagrilintide isn't a GLP-1 at all. It's an amylin analogue - amylin being a hormone the pancreas releases alongside insulin that promotes satiety and slows gastric emptying through its own receptor pathway. Different lever, same goal.

Paired with semaglutide in one weekly injection (CagriSema), REDEFINE-1 enrolled 3,417 adults with obesity and reported roughly 20.4% mean weight loss at 68 weeks, rising to about 22.7% among those who stayed fully on treatment - versus roughly 15–16% for semaglutide alone, 11.5% for cagrilintide alone, and about 3% for placebo, in the same trial. Novo Nordisk filed with the FDA in December 2025; a decision was expected during 2026.

And here is the finding that most coverage skips. REDEFINE-4 compared CagriSema head-to-head against Zepbound (tirzepatide) at its highest approved dose - and missed its primary endpoint of non-inferiority on weight loss, with 23.0% versus 25.5% at 84 weeks. This is the only genuine head-to-head on this page, and it went to tirzepatide.

So the fair summary is: CagriSema is a genuinely novel combination that clearly beats semaglutide alone, but it has not been shown to beat the existing best-in-class option. (Full guide.)

What about combining them yourself?

The obvious question once you see the pattern: if adding pathways works, why not stack retatrutide or tirzepatide with cagrilintide independently?

The honest answer is that nobody knows, and the reasoning that makes it tempting is also what makes it risky. Every combination above was developed as a fixed combination, tested as a unit, with the ratio between components deliberately chosen and studied across thousands of participants. CagriSema is not "cagrilintide plus semaglutide taken together" - it's a specific formulation whose safety and efficacy were established as a single product.

Three specific problems with self-combining:

• No safety data exists for the combination as used. Trials establish a benefit-risk profile for that combination at those ratios. Outside them, you have neither.
• GI tolerability compounds. Each of these slows gastric emptying. Stacking mechanisms that share a side-effect profile tends to stack the side effects, and dehydration, persistent vomiting and gallbladder problems are the events that put people in hospital.
• Muscle loss compounds too. More aggressive weight loss means more lean mass at risk. That's manageable with resistance training and adequate protein under supervision; it's not manageable when the weight is coming off faster than anyone is monitoring. (Muscle loss on GLP-1s.)

Combination therapy in this class is a clinical trial question, being actively answered by the manufacturers. The version worth having is the one that arrives with dosing established, monitored, and approved - not the version assembled from grey-market vials.

The bottom line - and where to start

The trajectory is real: one receptor, then two, then three, and the numbers climb each time. But the practical picture in August 2026 is narrower than the headlines suggest. Only semaglutide and tirzepatide are approved and available. Retatrutide and CagriSema, whatever their trial results, are not prescribable medicines yet.

And the newest is not automatically the best fit. Semaglutide holds the only proven mortality benefit. Tirzepatide is the most effective approved option and won the only head-to-head here. The right choice depends on your metabolic picture, comorbidities, tolerability and goals - a clinical decision, not a leaderboard.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore semaglutide.

Frequently asked questions

Is retatrutide better than tirzepatide? On published trial data retatrutide produced more weight loss (about 28.3% at 80 weeks versus about 21% for tirzepatide at 72 weeks), but these come from separate trials in different populations, not a head-to-head. More importantly, retatrutide is not approved anywhere and cannot legally be prescribed or compounded; tirzepatide is approved and available now.

Is CagriSema better than Zepbound? Not on the evidence available. REDEFINE-4 compared them head-to-head and CagriSema missed its non-inferiority endpoint against tirzepatide at its highest dose. CagriSema clearly outperforms semaglutide alone, but it has not been shown to beat tirzepatide.

Can you take retatrutide or tirzepatide with cagrilintide? There is no safety or efficacy data for self-combining these outside a trial. The approved and investigational combinations are fixed formulations tested as single products at specific ratios. Combining independently stacks shared side effects - particularly gastrointestinal - and accelerates lean mass loss without the monitoring the trials had. It's a question for clinical trials, not self-experimentation.

Which GLP-1 has the best long-term outcome data? Semaglutide. The SELECT trial in over 17,000 adults showed a 20% reduction in major adverse cardiovascular events and a 19% reduction in death from any cause - the only proven mortality benefit among the compounds compared here. Newer drugs produce more weight loss but have not yet demonstrated the same outcome benefits.

Related reading

• Semaglutide · Tirzepatide · Retatrutide · Mounjaro vs Wegovy vs Ozempic · New weight-loss drugs 2026–2027 · The peptides that actually matter · Ultra-long-acting monthly GLP-1s
• Part of The Complete Guide to GLP-1s

---

Educational content, not medical advice. No doses, titration schedules or administration details appear. Retatrutide and CagriSema are investigational and not approved; retatrutide cannot legally be compounded. Approved medicines require individual medical assessment and monitoring. Status stated as of August 2026 and changing. Claims for the Malaysian market are subject to MAB requirements.

References

• Semaglutide: STEP programme (~15% mean weight loss); SELECT (n>17,000, 20% MACE reduction, 19% all-cause mortality reduction); FDA label expansion 2024 for cardiovascular risk reduction. · Tirzepatide: SURMOUNT-1 (~21% at 72 weeks vs ~3% placebo); prediabetes progression reduced 94% in extended follow-up; FDA approvals 2022 (Mounjaro, T2D) and 2023 (Zepbound, weight management). · Retatrutide: Jastreboff AM et al., N Engl J Med 2023;389:514–526 (phase 2, 24.2% at 48 weeks); TRIUMPH-1 topline 28.3% at 80 weeks (n=2,339, reported May 2026); TRIUMPH-4 28.7% at 68 weeks (reported December 2025); TRIUMPH-2/-3 ~20.8%/~22.6%; TRANSCEND-T2D-1 16.8% weight loss and up to −2.0 HbA1c at 40 weeks (Lancet); Giblin K et al., Diabetes Obes Metab 2026;28(1):83–93 (TRIUMPH design); BLA anticipated Q1 2027; FDA: not approved, not eligible for compounding. · CagriSema: REDEFINE-1 (n=3,417, 68 weeks; ~20.4% treatment-policy and ~22.7% trial-product estimand vs ~15–16% semaglutide alone, ~11.5% cagrilintide alone, ~3% placebo), N Engl J Med 2025; REDEFINE-2 in type 2 diabetes; REDEFINE-4 head-to-head vs Zepbound (tirzepatide) at its highest approved dose (23.0% vs 25.5% at 84 weeks) - primary endpoint of non-inferiority on weight loss not met (February 2026); NDA submitted 18 December 2025.